Time Lapse Imaging Trial

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
04/04/2018		[X] Protocol		
Registration date	Overall study status	Statistical analysis plan		
18/04/2018	Completed	[X] Results		
Last Edited 22/07/2024	Condition category Pregnancy and Childbirth	[] Individual participant data		

Plain English summary of protocol

Background and study aims

In vitro fertilisation (IVF) techniques can help people with fertility problems to have a baby. In IVF an egg is fertilized by sperm in a test tube to create an embryo. The current methods of selecting the best embryo for replacement into the womb during IVF are imprecise. The resulting success rates for this expensive treatment are less than ideal. Success rates might be improved by a new technology that uses time-lapse imaging, where embryos are grown in a special incubator, and an inbuilt microscope and camera allows embryos to be assessed without having to remove them. In addition, images of the developing embryo are taken every five to fifteen minutes, which can give additional information (morphokinetic parameters) to aid selection. The aim of this study is to find out whether this technology increases the likelihood of live birth following fertility treatment.

Who can participate?

Couples undergoing IVF or ICSI (Intra-Cytoplasmic Sperm Injection) treatment, where the woman is between 18 and 42 years of age and the male partner is at least 18 years of age

What does the study involve?

Participants are randomly allocated to one of three treatment groups. In the first group embryos are grown in the time-lapse incubator using time-lapse imaging for embryo selection. In the second group embryos are grown in the time-lapse incubator using only standard assessment techniques. In the third group embryos are grown in standard incubators. At the end of the incubation (3-6 days after egg collection), the best embryo(s) are transferred. The woman is then followed up until a maximum of 6 weeks after the end of the pregnancy. The number of live births is taken from the patients' medical notes or by contacting the participant.

What are the possible benefits and risks of participating?

There is no guarantee that taking part in this study will increase the chances of IVF/ICSI being successful, but participants will be helping clinicians and policy makers decide whether current IVF/ICSI guidelines need to be changed. There is no added risk using this technology for the growth and monitoring of embryos. The camera captures embryos in red light for a very short period of time – 15 milliseconds. This is the same amount of light exposure as during manual removal of embryos from the standard incubator and their examination under a standard microscope. The time lapse imaging systems are CE marked.

Where is the study run from?

Barts Research Centre for Women's Health, Women's Health Research Unit, Queen Mary University of London, James Cook University Hospital (UK) and The Chinese University of Hong Kong Prince of Wales Hospital (Hong Kong)

When is the study starting and how long is it expected to run for? September 2017 to September 2023

Who is funding the study?

- 1. Barts and the London Charity and Related Charities (UK)
- 2. Pharmasure Ltd (UK)

Who is the main contact?

1. James Heighway

j.heighway@qmul.ac.uk

2. Priya Bhide

priya.bhide@nhs.net

Contact information

Type(s)

Scientific

Contact name

Mr James Heighway

Contact details

Barts Research Centre for Women's Health Institute of Population Health Sciences Queen Mary University of London Yvonne Carter Building 58 Turner Street London United Kingdom E1 2AB +44 (0)20 7882 3272 j.heighway@qmul.ac.uk

Type(s)

Scientific

Contact name

Dr Priya Bhide

ORCID ID

https://orcid.org/0000-0003-0871-6508

Contact details

Centre for Women's Health Institute of Population Health Sciences Bart's and the London School of Medicine and Dentistry Queen Mary University of London Yvonne Carter Building 58 Turner Street London United Kingdom E1 2AB

priya.bhide@nhs.net

Additional identifiers

Protocol serial number 37510

Study information

Scientific Title

A pragmatic, multi-centre, three-arm randomised controlled trial to assess the clinical effectiveness and safety of time lapse imaging in in-vitro fertilisation treatment

Acronym

TILT

Study objectives

Current methods of selecting the best embryo for replacement into the womb during in-vitro fertilisation treatment (IVF) are imprecise. The resulting success rates for this expensive treatment are less than ideal. Success rates might be improved by a new technology that uses time-lapse imaging, where embryos are grown in a special incubator, and an inbuilt microscope and camera allow embryos to be assessed without having to remove them. In addition, images of the developing embryo are taken every five to fifteen minutes, which can give additional information (so-called morphokinetic parameters) to aid selection. Current best evidence for the use of time-lapse imaging is uncertain and of moderate to low quality. The trialists propose to conduct a large-scale study giving high-quality evidence and a definitive answer to whether this technology increases the likelihood of live birth following fertility treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

London Central Research Ethics Committee, provisional approval 08/03/2018, ref: 18/LO/0330

Study design

Randomised; Interventional; Design type: Treatment, Device

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

In vitro fertilization

Interventions

A secure, web based randomisation system hosted by the Barts Women's Health Research Centre. The randomisation will be stratified by fertility clinic, and minimised by:

- 1. Participant's age (<35 years, 35 40 years, >40 years)
- 2. Type of planned first embryo transfer (fresh, frozen).

Participants are randomly allocated to one of three treatment groups:

Time-lapse imaging (intervention group 1): incubation and assessment of embryos within timelapse imaging systems, using morphokinetic parameters in addition to conventional morphological assessment

Undisturbed culture (intervention group 2): incubation of embryos in undisturbed culture conditions within time-lapse imaging incubators, using conventional morphological embryo assessment only

Standard care (control group): incubation of embryos in standard incubators, using conventional morphological embryo assessment only

At the end of the incubation (3-6 days after egg collection), the best embryo(s) will be transferred. The woman will then be followed up until a maximum of 6 weeks after the end of the pregnancy.

The sample size calculation was based upon the primary outcome of live birth. With a 5% overall significance level (2.5% for each of the two main treatment comparisons: TLI vs. standard care, and undisturbed culture vs. standard care), 514 participants would be required per treatment arm to detect an absolute increase in the primary outcome from 26.5% to 35.25% with 80% power. Allowing for 2% loss-to-follow-up or withdrawal of consent would require 525 participants per treatment arm (1575 in total). The comparison between experimental treatment arms (TLI vs. undisturbed culture) will be performed with no impact on sample size because this statistical test will be carried out conditional to the rejection of at least one of the primary comparisons planned (TLI vs. standard care, or undisturbed culture vs. standard care). This hierarchical approach permits to maintain the overall type I error rate of 5%.

Intervention Type

Other

Primary outcome(s)

Number of live births, taken from medical notes/contacting the participant; Timepoint(s): Delivery

Key secondary outcome(s))

Current secondary outcome measures as of 06/04/2020:

Clinical efficacy outcomes:

- 1. Pregnancy rate measured by pregnancy test taken from medical notes; Timepoint(s): 2 weeks after embryo transfer
- 2. Successful implantation of embryo(s) into womb measured by total number of gestational sacs seen on ultrasound scan/total number of embryos replaced into the womb taken from medical notes; Timepoint(s): 6-8 weeks after embryo transfer.
- 3. Successful clinical pregnancy measured by at least one intrauterine gestational sac taken from medical notes/contacting the participant; Timepoint(s): 6-8 weeks after embryo transfer

- 4. Use of elective single embryo transfer (e-SET) recorded per participant, taken from medical notes; Timepoint(s): At embryo transfer
- 5. Embryo utilization rate (% of total embryos either transferred or frozen), taken from medical notes; Timepoint: 2-6 days after date of fertilisation check.

Clinical safety outcomes:

- 1. Multiple pregnancy measured by two or more gestational sacs seen on ultrasound scan taken from medical notes/contacting the participant; Timepoint(s): 6-8 weeks after embryo transfer
- 2. Pregnancy loss recorded from medical notes/contacting the participant; Timepoint(s):
- 2.1. Between positive pregnancy test and 6-8 week scan
- 2.2. Between 6-8 week scan and 12 weeks (early miscarriage)
- 2.3. Between 12 and 24 weeks
- 2.4. Stillbirth
- 3. Incidence of major congenital abnormality at birth recorded as a Serious Adverse Event taken from medical notes/contacting the participant; Timepoint(s): Within 6 weeks of delivery
- 4. Birth weight, taken from medical notes; Timepoint: Delivery
- 5. Gestational age, taken from medical notes; Timepoint: Delivery
- 6. Ectopic pregnancy, taken from medical notes/contacting the participant; Timepoint(s): early pregnancy scan (6-8 weeks) & 24 weeks assessment

Previous secondary outcome measures:

Clinical efficacy outcomes:

- 1. Pregnancy rate measured by pregnancy test taken from medical notes; Timepoint(s): 2 weeks after embryo transfer
- 2. Successful implantation of embryo(s) into womb measured by total number of gestational sacs seen on ultrasound scan/total number of embryos replaced into the womb taken from medical notes; Timepoint(s): Two weeks after embryo transfer
- 3. Successful clinical pregnancy measured by at least one intrauterine gestational sac taken from medical notes/contacting the participant; Timepoint(s): 6-8 weeks after embryo transfer
- 4. Use of elective single embryo transfer (e-SET) recorded per participant, taken from medical notes; Timepoint(s): At embryo transfer

Clinical safety outcomes:

- 1. Multiple pregnancy measured by two or more gestational sacs seen on ultrasound scan taken from medical notes/contacting the participant; Timepoint(s): 6-8 weeks after embryo transfer
- 2. Miscarriage recorded for each pregnancy loss taken from medical notes/contacting the participant; Timepoint(s): Between 6 and 24 weeks gestation
- 3. Stillbirth recorded as pregnancy loss taken from medical notes/contacting the participant; Timepoint(s): After 24 weeks gestation
- 4. Incidence of major congenital abnormality at birth recorded as a Serious Adverse Event taken from medical notes/contacting the participant; Timepoint(s): Within 6 weeks of delivery

Completion date

30/09/2023

Eligibility

Key inclusion criteria

The inclusion criteria are broad in keeping with the latest NICE guidelines (2013) for NHS funded IVF/ICSI treatment.

Participants undergoing IVF/ICSI treatment and:

- 1. The woman is between 18 and 42 years of age at the time of consent
- 2. The male partner is at least 18 years of age at the time of consent
- 3. Receiving the first, second or third IVF/ICSI treatment cycle
- 4. Both partners give written informed consent
- 5. Those having at least 3 2PN embryos (showing 2 pro-nucleii which is a sign of normal fertilisation) on day of fertilization check

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

1575

Key exclusion criteria

Current exclusion criteria as of 06/04/2020:

- 1. Participants concomitantly participating in other interventional trials
- 2. IVF/ICSI treatment using donor gametes
- 3. Planned pre-implantation genetic diagnostics or screening (PGS/PGD)

Previous exclusion criteria:

- 1. Participants who have been randomised previously to this trial
- 2. Participants concomitantly participating in other trials
- 3. IVF/ICSI treatment using donor gametes
- 4. Planned pre-implantation genetic diagnostics or screening (PGS/PGD)

Date of first enrolment

01/05/2018

Date of final enrolment

30/09/2022

Locations

Countries of recruitment

United Kingdom

England

Hong Kong

Study participating centre Homerton University Hospital

Homerton Row London United Kingdom E9 6SR

Study participating centre St Bartholomews Hospital

Centre for Reproductive Medicine 1st Floor, Kenton & Lucas Wing West Smithfield London United Kingdom EC1A 7BE

Study participating centre Bath Fertility Centre

Roman Way Bath Business Park Peasedown St John Bath United Kingdom BA2 8SG

Study participating centre Hammersmith Hospital

Du Cane Road White City London United Kingdom W12 0HS

Study participating centre Complete Fertility Centre- Princess Anne Hospital Mailpoint 105, Level G Coxford Road

Southampton United Kingdom SO16 5YA

Study participating centre
Ocean Suite- Derriford Hospital
South West Centre for Reproductive Medicine
Ocean Suite, Level 6
Derriford Hospital
Plymouth
United Kingdom
PL6 8DH

Study participating centre
Assisted Reproductive Technology (ART) Unit
Department of Obstetrics & Gynaecology
The Chinese University of Hong Kong
9F, Special Block EF
Prince of Wales Hospital
Shatin, N.T.
Hong Kong

Sponsor information

Organisation

Queen Mary University of London

ROR

https://ror.org/026zzn846

Organisation

Chinese University of Hong Kong

Funder(s)

Funder type

Charity

Funder Name

Barts and the London Charity and Related Charities; Grant Codes: MGU0374

Funder Name

Pharmasure Ltd

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from the CI Dr Priya Bhide (p.bhide@qmul.ac.uk). There will be restrictions on the availability of raw data for this study, due to data confidentiality and patient privacy. Researchers wishing to access the TILT trial data for the purposes of replicating or verifying our analyses can apply to the CI at the BARC (Barts Research Centre for Women's Health).

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		20/07/2024	22/07/2024	Yes	No
<u>Protocol article</u>	protocol	01/07/2020	05/07/2020	Yes	No
HRA research summary			28/06/2023		No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes